RVT-1801

N/A

Report date: 2023/10/26 17:10:57

Base Information

Drug NameRVT-1801

Drug Alias NameRVT-1801ARU-1801

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionGene transferenceFetal hemoglobin inducers

TargetsFetal hemoglobin

Therapy Area/IndicationsThalassemiaAnemia, Sickle Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAruvant Sciences Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsThalassemiaAnemia, Sickle Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A